Listed price
$119/month
Supply description
Monthly vial
Consultations
Included in published price
Shipping
Included in published price
Renewal
Auto-refill
Related format
Separate $99 oral lozenge listing

Use the injection card rather than a combined headline

Strut Health's detailed pricing section lists its injectable sermorelin at $119 for a monthly vial. The company also sells a lozenge, but that is a separate product with a different price. Select the injection explicitly when checking the offer, and verify that the confirmation screen names the same route and product.

The term “monthly vial” supplies a billing context, not a standardized amount shared by all providers. The final prescription should identify concentration, total quantity and expected supply period before a reader attempts a like-for-like cost comparison.

Included care reduces some budget uncertainty

Physician consultations and shipping are included in the published price. The page also advertises free follow-ups and access to provider messaging. This makes the plan more informative than a headline that does not distinguish medication charges from clinical access.

Laboratory costs are not established by those statements. Ask whether testing is required for the proposed plan, whether it is available through Strut or an outside laboratory and who pays. Also confirm which administration supplies arrive with the vial, since a free consultation does not answer a question about physical supplies.

An injection requires pharmacy-specific instructions

The provider describes a subcutaneous route. This review does not reproduce a dosing schedule because the prescriber and pharmacy must specify how the actual formulation is used. The concentration, measuring device and preparation instructions on an individualized order matter more than a generic page description.

Ask the pharmacist how the vial must be stored, when it should be discarded and what to do if shipment is delayed or exposed to unsuitable conditions. A beyond-use date can affect usable supply independently of the nominal amount in the vial. Include that question before ordering extra quantities for convenience.

What the clinical language does and does not show

Strut discusses growth-hormone signaling and possible changes in sleep, recovery and mental clarity. These are not outcomes independently measured by this publication. The page's comparison with synthetic growth hormone does not establish that a particular patient will experience fewer harms or better results.

The injection is compounded and not FDA-approved. Ask the clinician how the proposed treatment relates to your medical history, what evidence supports your specific goal and what follow-up would make the ongoing expense worthwhile. A monthly subscription should not replace a defined point for reassessing the plan.

Auto-refill is part of the purchase

The product page describes auto-refill and cancellation at any time. Obtain the actual cutoff before the next prescription enters pharmacy processing, and confirm whether pausing a shipment also pauses billing. If the clinician changes or stops treatment, request written confirmation that the prior order will not renew.

Twelve unchanged $119 charges would total $1,428 before unresolved additional costs. That example is a budget calculation rather than a treatment-duration recommendation. Strut's injection offer is most comparable when the quote retains the clinical inclusions, the exact vial details and the renewal terms alongside the monthly number.

Useful distinctions

  • Consultations and shipping included
  • Specific injection price
  • Provider messaging advertised

Limitations to weigh

  • Laboratory and supply inclusions need confirmation
  • Auto-refill deadline not established
  • No equivalence claim with oral product

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. Strut Health: Sermorelin injection and oral lozenge Provider
  2. FDA: Understanding the Risks of Compounded Drugs Regulatory